{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-066904","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.731208+00:00","generated_at":"2026-06-11T13:30:17.219292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emmaus Life Sciences reports record Q2 net revenue of $10.8M; posts $3.3M income from operations","bullets":["Q2 net revenue $10.8M (up 151% YoY); six-month net revenue $17.5M (up 133% YoY).","Q2 income from operations $3.3M vs loss of $1.4M in Q2 2022; six-month income $2.2M vs loss of $4.5M.","Net loss narrowed to $1.5M ($0.03/sh) from $8.9M ($0.18/sh) in Q2 2022; six-month loss $5.0M ($0.10) vs $10.4M ($0.21).","Sales growth driven by $4.1M increase in MENA region in Q2; U.S. sales also recovering.","Cash and equivalents $1.4M at June 30, 2023, down from $2.0M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-066904","json":"https://secwatch.observer/filing/0001213900-23-066904.json","markdown":"https://secwatch.observer/filing/0001213900-23-066904.md","text":"https://secwatch.observer/filing/0001213900-23-066904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390023066904/0001213900-23-066904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390023066904/ea183077-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:30:17.219292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f13f9ae046161ed7ebd1b8258d63ea49e9ed10b5","claim":"Emmaus Life Sciences, Inc. reported three and six months ended June 30, 2023 results: revenue $10.8 million and $17.5 million, net income net loss of $1.5 million, or $0.03 per share, EPS $0.03 per share.","evidence_excerpt":"Net revenues for the three months and six months ended June 30, 2023 were $10.8 million and $17.5 million, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390023066904/0001213900-23-066904-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Revenue","value":"$10.8 million and $17.5 million"},{"label":"Net income","value":"net loss of $1.5 million, or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}